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 19 
Outer membrane vesicles (OMVs) shed from bacteria contribute to pathogenesis by 20 
promoting colonisation of host tissues and trafficking virulence factors into host cells via 21 
fusion with the host cell plasma membrane. Glyeraldehyde-3-phosphate dehydrogenase 22 
(GAPDH) is also secreted by prokaryotes, but enhances pathogenesis by promoting adhesion 23 
of bacteria to host cell surfaces. However, GAPDH is also known to catalyse the fusion of 24 
membranes, and it has been shown to promote OMV activity in the non-pathogen 25 
Myxococcus xanthus. We suggest that during infection by Gram-negative bacteria, GAPDH 26 
and OMVs work synergistically to stimulate pathogenesis.  27 
 28 
Outer membrane vesicles in health and disease 29 
 30 
A common bacterial mechanism for engineering the environment involves the secretion of 31 
OMVs - 10-300 nm diameter packages, pinched off from the outer membrane of Gram-32 
negative bacteria, enclosing periplasmic material (Figure 1). OMV constituents can be 33 
specifically targeted for inclusion in OMVs, however the mechanisms of OMV biogenesis 34 
and cargo targeting remain poorly defined (Kulkarni and Jagannadham, 2014).  35 
 36 
OMVs are able to migrate away from their producing cells, accessing niches unavailable to 37 
the producing cell, and delivering secreted material to distant sites of action. Packaging 38 
within OMVs means their contents are not diluted as they are transported far from the cell, 39 
are protected from the environment (eg. extracellular proteases), and cargo complexes can be 40 
secreted as pre-assembled entities (Ellis and Kuehn, 2010; Kulkarni and Jagannadham, 2014). 41 
At their site of action, OMVs can deliver their contents by two mechanisms. They can fuse 42 
with target membranes (Figure 1) (Kadurugamawa and Beveridge, 1999; Bomberger et al., 43 
2009), or contact with a surface can trigger OMV lysis (Kadurugamuwa and Beveridge, 44 
1996), releasing OMV contents.  45 
 46 
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OMVs are produced by all Gram-negative bacteria, and are known to have diverse 47 
antimicrobial, biofilm-promoting, virus-resistance, quorum-signalling and virulence-48 
enhancing properties (Manning and Kuehn, 2013). The virulence of pathogens is known to 49 
correlate with the degree of vesiculation (Rolhion et al., 2005), and OMVs are able to 50 
enhance colonisation of host tissues, modify host cell biology, and/or protect the OMV-51 
producer from therapeutics and the host immune response (Inagaki et al., 2006; Thay et al., 52 
2014; Vanhove et al., 2015).  53 
 54 
OMV production is induced by stresses associated with host colonisation (McBroom and 55 
Kuehn, 2007), for example by exposure to host muscle tissue (Dutson et al., 1971). They are 56 
able to adhere to host cells (Inagaki et al, 2006), and promote biofilm formation in clinically 57 
important bacteria (Grenier and Mayrand, 1987; Kamaguchi et al 2003; Yonezawa et al., 58 
2009). The OMVs of many pathogens have been documented to contain toxins and other 59 
virulence factors (Thay et al., 2014; Roier et al., 2014; Elluri et al., 2014; Vanhove et al., 60 
2015), and OMV-packaging has been shown to stabilise, activate and/or regulate toxin 61 
activity (Fahie et al., 2013; Bielaszewska et al., 2014; Elluri et al., 2014).  62 
 63 
The gifted enzyme glyceraldehyde-3-phosphate dehydrogenase 64 
 65 
GAPDH (EC 1.2.1.12) is first encountered by biology students as an essential enzyme of 66 
central metabolism. It is a highly conserved protein, typically found as a tetramer (Seidler, 67 
2013), and can be post-translationally modified in multiple ways (Sirover, 2014).  68 
 69 
Intriguingly, GAPDH has been ascribed many additional roles beyond metabolism in 70 
eukaryotes, including glycosylation of uracil in DNA, transcriptional activation and apoptotic 71 
regulation (Sirover, 2005). One of its more exotic ‘moonlighting’ activities is the ability to 72 
fuse membranes together (Glaser and Gross, 1995). This can occur in vitro, but has also been 73 
implicated in the fusion of secretory granules with the plasma membrane in neutrophils, 74 
fusion of presynaptic vesicles with the synaptic membrane (and their loading with cargo), 75 
axoplasmic transport, ER-Golgi vesicular shuttling, and nuclear membrane fusion (Glaser and 76 
Gross, 1995; Hessler et al., 1998; Nakagawa et al., 2003; Ikemoto et al., 2003). The structural 77 
basis of fusogenesis is unknown, however fusion requires binding to the relatively scarce 78 
membrane lipid phosphatidylserine (PS), and the PS binding site of GAPDH has been 79 
elucidated (Kaneda et al., 1997).  80 
 81 
The classic glycolytic role of GAPDH places it in the cytoplasm, and it lacks an N-terminal 82 
signal sequence or other trafficking motif. However with the advent of proteomics, many 83 
studies have identified GAPDH in extracellular fractions of a wide range of bacteria (Vanden 84 
et al., 2013; Deng at al., 2012; Holland et al., 2010; Curtis et al., 2007; Wang et al., 2013). It 85 
is a major surface protein of Gram-positive (Pancholi and Fischetti, 1992; Pasztor et al., 86 
2010; Oliveira et al., 2012), and Gram-negative bacteria (Egea et al., 2007; Gao et al., 2014). 87 
In streptococci its release beyond the cell involves autolysis, with released protein then 88 
specifically binding to the surface of unlysed cells (Terrasse et al., 2015). Thus GAPDH 89 
seems to be an almost ubiquitous protein, being commonly found within cells, on cells and 90 
beyond cells. 91 
 92 
Extracellular bacterial GAPDH promotes adhesion to and invasion of host tissue, inhibits 93 
host lysozyme, and triggers apoptosis in macrophages (Seidler and Siedler, 2013). During 94 
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host colonisation, it is known to adhere to a variety of substrates, including PS, mucin, 95 
plasminogen and fibrinogen (Egea et al., 2007; Alvarez et al., 2013; Gao et al., 2014). It is 96 
likely that further mechanisms exist by which GAPDH promotes virulence, but studies have 97 
been hampered by difficulties in deleting the gene encoding GAPDH, due to its essential role 98 
in energy metabolism (Henderson and Martin, 2011). 99 
 100 
OMVs and GAPDH working together 101 
 102 
The soil-dwelling myxobacterium Myxococcus xanthus is a predator of a wide range of 103 
bacteria and fungi, and OMVs are implicated in several aspects of its life-cycle (Whitworth, 104 
2011). Its OMVs are loaded with hydrolases and they are able to kill other microbes, 105 
including Escherichia coli and Pseudomonas aeruginosa (Evans et al., 2012). Adding 106 
GAPDH to M. xanthus OMVs enhances their ability to kill prey cells. This is attributable to 107 
the fusogenic activity of the enzyme, as only intact OMVs exhibit cytotoxic activity (Evans et 108 
al., 2012), and OMVs of other bacteria are known to kill prey cells through fusion with their 109 
outer membrane (Kadurugamuwa and Beveridge, 1996). GAPDH has been found to be a 110 
major component of M. xanthus cells, OMVs and soluble secretome (Whitworth et al., 2015) 111 
suggesting GAPDH stimulates the antimicrobial activity of M.  xanthus OMVs in the wild, by 112 
promoting their fusion with prey cells. 113 
 114 
EVpedia, the EV database (Kim et al., 2013), shows that GAPDH has been observed as a 115 
component of the OMVs of many organisms (including E. coli, P. aeruginosa, Edwardsiella 116 
tarda, Francisella tularensis, F. philomiragia, Acinetobacter baumanii, and Neiserria 117 
meningiditis). Given the virtual ubiquity of GAPDH and OMV secretion, it is possible they 118 
could be working together in other contexts. The bacterial behaviour for which there is most 119 
evidence of potential GAPDH-OMV synergy is pathogenesis. If the activities analogous to 120 
those observed for M. xanthus occur for pathogens in vivo, then pathogen OMVs would be 121 
stimulated to fuse with target cells/membranes by pathogen-derived GAPDH.  122 
 123 
GAPDH/OMV co-operation during pathogenesis 124 
 125 
There are several lines of evidence described above which suggest such GAPDH/OMV 126 
synergy:  127 
 Both GAPDH and OMVs are secreted commonly (ubiquitously?) by pathogens. 128 
 Both GAPDH and OMVs stimulate pathogenesis.  129 
 GAPDH is a common component of OMVs 130 
 GAPDH is an adhesin, but also has membrane fusion activity. 131 
 OMVs can deliver their contents beyond target membranes by fusing with them. 132 
 GAPDH can enhance OMV activity by stimulating membrane fusion. 133 
 134 
Pathogen-derived GAPDH has been shown to have a mechanistic role in tissue colonisation 135 
and adherence, but in no other aspects of the pathogenicity of Gram-negative organisms. 136 
However, making a topological mutant that does not secrete GAPDH results in a strain with 137 
reduced (but not abolished) host cell adherence (Boël et al., 2005), indicating that pathogens 138 
have other adhesins that complement GAPDH’s matrix-binding activity. Nevertheless, non-139 
pathogenic strains of E. coli do not secrete GAPDH (Egea et al., 2007), which is taken as 140 
evidence that GAPDH is required for pathogenicity. Together these observations suggest that 141 
GAPDH has a role in virulence beyond just adhesion. 142 
 143 
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The few studies that have demonstrated membrane fusion by OMVs have taken no effort to 144 
reduce GAPDH levels/activity in their OMV preparations, and the organisms whose OMVs 145 
are known to fuse with membranes are also known to naturally contain GAPDH. GAPDH 146 
may be merely promoting an intrinsic OMV activity, but the possibly cannot be discounted 147 
that GAPDH is actually required for OMV membrane-fusion activity and resulting toxin 148 
delivery. 149 
 150 
An interesting mechanistic feature common to OMV uptake and GAPDH-catalysed 151 
membrane fusion is that both processes are thought to be dependent on specific lipids. The 152 
fusogenic activity of GAPDH requires cholesterol and the ether lipid plasmenylethanolamine, 153 
which are both commonly found in mammalian membranes (Glaser and Gross, 1995). Kesty 154 
et al. (2004) showed that enterotoxigenic E. coli secretes enterotoxin via OMVs, and that host 155 
cells were able to endocytose the toxin-containing OMVs by a mechanism dependent on 156 
cholesterol-rich lipid rafts. In principle, GAPDH could stimulate OMVs to bind to 157 
cholesterol-rich membranes, which are then prime substrates for GAPDH-mediated fusion or 158 
host-mediated endocytosis (with delivery of OMV contents into the target cell). 159 
 160 
There is also the potential for OMVs to affect GAPDH function reciprocally. OMVs increase 161 
the effective amount of bacterial OM, which GAPDH can cross-link by virtue of its 162 
properties as an adhesin, potentially promoting biofilm formation and uptake/fusion of 163 
OMVs.  164 
 165 
Beyond pathogenesis 166 
 167 
As OMVs and GAPDH appear to be ubiquitously secreted by Gram-negative bacteria, it is 168 
likely that GAPDH will be implicated in other functions of OMVs. Biofilm formation is an 169 
important and universal phenomenon, promoted by OMVs. It is also promoted by 170 
intercellular quorum signalling which itself can be transduced through OMVs (Mashburn and 171 
Whiteley, 2005). Mixed biofilms are frequently observed in nature, and competition between 172 
the different inhabitants is important for determining fitness. Delivery of toxins to 173 
competitors or prey organisms via OMVs has been observed and thus modulation of OMV 174 
activity by GAPDH would likely be an important fitness determinant. 175 
 176 
In the laboratory, several obvious experiments arise from considering the potential 177 
involvement of GAPDH in OMV activity.  178 
 No bacterial GAPDH has yet been shown to possess fusogenic activity and this needs 179 
to be confirmed, perhaps by monitoring lipid/content mixing through fluoresence 180 
quenching/enhancement (Glaser and Gross, 1994). Care would need to be taken 181 
however as GAPDH-mediated membrane fusion may be dependent on membrane 182 
lipid composition as it is in eukaryotes (Glaser and Gross, 1995). 183 
 We would expect GAPDH-depleted OMVs to be impeded in their ability to fuse with 184 
target membranes. This would be a technically challenging prediction to test however, 185 
due to the important metabolic role of GAPDH precluding facile gene deletion, and 186 
the inherent membrane-binding affinity of GAPDH defying physical removal. 187 
Nevertheless it should be possible to engineer a GAPDH deletant by developing 188 
appropriate media to support metabolic bypassing of glycolysis/gluconeogenesis in 189 
the mutant. Alternatively a ‘functional’ mutant could be created by placing the 190 
GAPDH gene under the control of an inducible or repressible promoter, or through 191 
the creation of a topologically restricted version of GAPDH (Boël et al., 2005). 192 
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GAPDH inhibitors are also available, which might also affect fusogenic activity (eg. 193 
pentalenolactone and koningic (heptelidic) acid). 194 
 GAPDH is expected to promote adhesion between bacterial cells, as well as cell-195 
OMV adhesion. It would be interesting to see whether reducing membrane-associated 196 
GAPDH levels does impact negatively on colonial growth and/or aggregation. 197 
Perhaps by using simple assays which monitor sedimentation of aggregated cells, for 198 
example the approach used by Chang and Dworkin (1994) to measure bacterial 199 
cohesion. 200 
 The effect of cholesterol and/or ether lipids on GAPDH-mediated OMV-membrane 201 
fusion should be tested for a range of OMV producers and target membranes, to 202 
delineate any conservation of lipid requirements.  203 
 204 
Implications 205 
 206 
Bacterial GAPDH has already proven useful as a therapeutic target with the development of 207 
cross-protective GAPDH-based vaccines against Gram-negative and –positive bacteria for 208 
agri- and aqua-culture (Li et al., 2011; Vanden et al., 2013; Velineni and Timoney, 2013; 209 
Trung et al., 2014). The GAPDH inhibitor pentalenolactone (Cane and Sohng, 1994) is 210 
known to act as an antibiotic due to its disruption of bacterial glycolysis, but it is also potent 211 
against mammalian homologues and is not used in the clinic. Nevertheless there are enough 212 
sequence differences between human and bacterial GAPDH to make GAPDH-targeted 213 
therapies for the clinic plausible (Seidler and Seidler, 2013), and such inhibitors could also be 214 
useful beyond the clinic as antibiofilm/antifouling compounds. 215 
 216 
OMVs are proving efficacious as hapten components of antibacterial vaccines (Acevedo et 217 
al., 2014; Choi et al., 2014; Nieves et al., 2014), and as adjuvants for delivery of heterologous 218 
haptens (Moshiri et al., 2012). Perhaps part of the success of OMV vaccines is because they 219 
are multivalent GAPDH-presenting entities. Rationally combining GAPDH and OMVs 220 
within vaccines has the potential to synergistically enhance immunogenicity of each 221 
component. It is plausible that OMVs could also see use in the clinic as antimicrobials. Not 222 
only have they been shown to kill bacteria directly but they can also act as delivery devices 223 
for antibiotics (Kadurugamuwa and Beveridge, 1998). Potentially, the addition of stimulatory 224 
‘accessory proteins’ such as GAPDH would help make such OMV-based approaches more 225 
effective. 226 
 227 
Beyond the clinic, a holistic understanding of the interaction between GAPDH and OMVs 228 
will need to consider the relative physical location of both entities and modulators of their 229 
activities. This will be especially important when considering mixed communities of bacteria, 230 
expressing a range of OMVs and GAPDH isoforms with differing target specificities and 231 
fusogenic potential. However an enhanced understanding of such processes will provide 232 
invaluable information regarding the mechanisms of bacterial competition and co-operation. 233 
 234 
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Figure legend 412 
 413 
Figure 1. OMV production and targeting to a eukaryotic cell. A Gram-negative cell (top) 414 
produces an OMV (middle) by pinching-off a protrusion of the outer membrane (OM). The 415 
OMV is enriched in a subset of OM and periplasmic (PP) material, including specific 416 
proteins and peptidoglycan fragments (grey), while inner membrane (IM) and cytoplasmic 417 
(CYT) material is absent. The OMV is able to fuse with a target membrane (bottom), in this 418 
case the plasma membrane (PM) of a eukaryotic cell, delivering its contents into the PM and 419 
cytoplasm (CYT). GAPDH (yellow squares) is found on the surface of cells and OMVs, and 420 
can stimulate the fusion of OMVs with target membranes. 421 
 422 
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